X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-18 | AAOI | Applied Optoelectronics, Inc. | Lin Chih-Hsiang (Thompson) | Pres, CEO | P - Purchase | $12.66 | +11,780 | 1,218,160 | +1% | +$149,169 | ||||||
2024-02-06 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | P - Purchase | $4.39 | +20,000 | 528,260 | +4% | +$87,800 | ||||||
D | 2024-03-04 | ACHV | Achieve Life Sciences, Inc. | Stewart Richard Alistair | Exec COB | P - Purchase | $4.59 | +10,000 | 38,501 | +35% | +$45,850 | |||||
D | 2024-03-04 | ACHV | Achieve Life Sciences, Inc. | Bencich John | CEO | P - Purchase | $4.59 | +10,000 | 76,724 | +15% | +$45,850 | |||||
2024-03-11 | ACLS | Axcelis Technologies Inc | Low Russell | Pres, CEO | P - Purchase | $112.39 | +440 | 57,754 | +1% | +$49,452 | ||||||
2024-02-23 | ACLS | Axcelis Technologies Inc | Lawson Douglas A. | EVP, Corporate Mktg, Strategy | P - Purchase | $111.04 | +500 | 19,648 | +3% | +$55,520 | ||||||
2024-02-29 | ACLS | Axcelis Technologies Inc | Coogan James Gordon | EVP, CFO | P - Purchase | $112.23 | +100 | 5,991 | +2% | +$11,223 | ||||||
2024-01-12 | AEHR | Aehr Test Systems | Ray-Chaudhuri Avijit K. | EVP of R, D | P - Purchase | $17.87 | +3,000 | 9,719 | +45% | +$53,600 | ||||||
2024-02-15 | AGEN | Agenus Inc | Armen Garo H | See Remarks | P - Purchase | $0.65 | +500,000 | 2,436,483 | +26% | +$324,050 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.33 | +75,758 | 716,455 | +12% | +$25,000 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Rodino Peter W III | COO, Secretary, Gen. Counsel | P - Purchase | $0.33 | +37,879 | 181,718 | +26% | +$12,500 | ||||||
2024-01-29 | AKTS | Akoustis Technologies, Inc. | Aichele David | EVP of Business Development | P - Purchase | $0.50 | +80,000 | 334,622 | +31% | +$40,000 | ||||||
2024-01-29 | AKTS | Akoustis Technologies, Inc. | Boller Kenneth | CFO | P - Purchase | $0.50 | +60,000 | 214,957 | +39% | +$30,000 | ||||||
2024-01-29 | AKTS | Akoustis Technologies, Inc. | Shealy Jeffrey B. | CEO | P - Purchase | $0.50 | +1,310,000 | 2,222,775 | +144% | +$655,000 | ||||||
2024-03-14 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | CEO | P - Purchase | $11.31 | +4,400 | 171,620 | +3% | +$49,771 | ||||||
2024-01-22 | AMRN | Amarin Corp Plcuk | Holt Patrick | Pres, CEO | P - Purchase | $1.09 | +14,426 | 314,426 | +5% | +$15,724 | ||||||
2024-03-15 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.22 | +30,000 | 491,925 | +6% | +$96,600 | ||||||
2024-02-06 | ANRO | Alto Neuroscience, Inc. | Smith Nicholas Conrad | CFO | P - Purchase | $16.00 | +1,563 | 1,563 | New | +$25,008 | ||||||
D | 2024-02-06 | ANRO | Alto Neuroscience, Inc. | Etkin Amit | Pres, CEO | P - Purchase | $16.00 | +3,125 | 1,205,465 | 0% | +$50,000 | |||||
D | 2024-02-06 | ANRO | Alto Neuroscience, Inc. | Savitz Adam | CHIEF MEDICAL OFFICER | P - Purchase | $16.00 | +17,000 | 24,851 | +217% | +$272,000 | |||||
D | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $7.29 | +1,010 | 15,503 | +7% | +$7,363 | |||||
D | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Gilad Oren | Pres, CEO | P - Purchase | $7.29 | +2,000 | 324,770 | +1% | +$14,580 | |||||
2024-02-13 | ASYS | Amtech Systems Inc | Daigle Robert C | COB, CEO | P - Purchase | $4.21 | +3,500 | 103,702 | +3% | +$14,735 | ||||||
2024-01-16 | AVDL | Avadel Pharmaceuticals Plc | McHugh Thomas S | CFO | P - Purchase | $14.50 | +2,000 | 80,500 | +3% | +$29,000 | ||||||
2024-02-13 | AZTR | Azitra, Inc. | Salva Francisco D. | Pres, CEO | P - Purchase | $0.30 | +333,300 | 338,300 | >999% | +$99,990 | ||||||
2024-03-14 | BALL | Ball Corp | Fisher Daniel William | Pres, C.E.O. | P - Purchase | $64.56 | +3,869 | 125,685 | +3% | +$249,767 | ||||||
2023-12-20 | BCAB | Bioatla, Inc. | Short Jay M Phd | CEO, 10% | P - Purchase | $2.14 | +50,000 | 3,052,658 | +2% | +$106,910 | ||||||
D | 2024-02-13 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.46 | +108,108 | 555,447 | +24% | +$50,000 | |||||
2024-02-09 | BERY | Berry Global Group, Inc. | Kwilinski Kevin J. | CEO | P - Purchase | $57.44 | +2,000 | 2,000 | New | +$114,880 | ||||||
M | 2023-12-04 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.06 | +96,500 | 2,120,112 | +5% | +$5,710 | |||||
M | 2019-03-22 | CAL | Caleres Inc | Schmidt John W | Pres, CEO, Caleres | P - Purchase | $23.54 | +2,000 | 343,672 | +1% | +$47,075 | |||||
2024-01-24 | CATX | Perspective Therapeutics, Inc. | Puhlmann Markus | Chief Medical Officer | P - Purchase | $0.50 | +280,000 | 1,375,425 | +26% | +$139,888 | ||||||
2024-03-14 | CE | Celanese Corp | Kelly Thomas Francis | SVP, EM | P - Purchase | $156.70 | +1,400 | 57,023 | +3% | +$219,373 | ||||||
2024-03-08 | CE | Celanese Corp | Murray Mark Christopher | SVP - Acetyls | P - Purchase | $156.43 | +597 | 11,600 | +5% | +$93,389 | ||||||
2024-01-29 | CGON | Cg Oncology, Inc. | Roche Corleen M. | CFO, Secretary | P - Purchase | $19.00 | +2,000 | 2,000 | New | +$38,000 | ||||||
2024-01-29 | CGON | Cg Oncology, Inc. | Kasturi Vijay | Chief Medical Officer | P - Purchase | $19.00 | +1,315 | 1,315 | New | +$24,985 | ||||||
2024-03-14 | CGTX | Cognition Therapeutics Inc | Ricciardi Lisa | CEO, Pres | P - Purchase | $1.75 | +5,700 | 291,345 | +2% | +$9,975 | ||||||
D | 2024-02-01 | CNSP | Cns Pharmaceuticals, Inc. | Climaco John M | CEO | P - Purchase | $0.30 | +166,666 | 215,676 | +340% | +$50,000 | |||||
D | 2024-02-01 | CNSP | Cns Pharmaceuticals, Inc. | Downs Christopher | CFO | P - Purchase | $0.30 | +66,666 | 103,438 | +181% | +$20,000 | |||||
M | 2024-01-05 | COEP | Coeptis Therapeutics Holdings, Inc. | Mehalick David | CEO, Pres, 10% | P - Purchase | $0.67 | +25,054 | 2,782,615 | +1% | +$16,747 | |||||
2024-01-05 | COEP | Coeptis Therapeutics Holdings, Inc. | Yerace Daniel Alexander | VP of Operations | P - Purchase | $0.69 | +10,850 | 1,071,455 | +1% | +$7,487 | ||||||
M | 2024-03-13 | COOK | Traeger, Inc. | Andrus Jeremy | CEO | P - Purchase | $2.35 | +396,689 | 16,032,474 | +3% | +$933,006 | |||||
2024-03-13 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | P - Purchase | $3.74 | +13,561 | 352,839 | +4% | +$50,718 | ||||||
2024-02-12 | CTLP | Cantaloupe, Inc. | Venkatesan Ravi | CEO | P - Purchase | $6.45 | +7,749 | 128,658 | +6% | +$49,981 | ||||||
2024-01-04 | CW | Curtiss Wright Corp | Freda Robert F | VP, Treasurer | P - Purchase | $189.32 | +49 | 3,382 | +1% | +$9,277 | ||||||
2024-01-04 | CW | Curtiss Wright Corp | Watts John C | VP Strat, Bus Dev | P - Purchase | $189.32 | +30 | 3,553 | +1% | +$5,680 | ||||||
2024-01-04 | CW | Curtiss Wright Corp | Bamford Lynn M | Chair, CEO | P - Purchase | $189.32 | +52 | 19,112 | 0% | +$9,845 | ||||||
2024-01-04 | CW | Curtiss Wright Corp | Farkas K Christopher | VP, CFO | P - Purchase | $189.32 | +51 | 9,172 | +1% | +$9,655 | ||||||
2024-01-04 | CW | Curtiss Wright Corp | Ferdenzi Paul J | VP, Corp. Sec. | P - Purchase | $189.32 | +42 | 17,124 | 0% | +$7,951 | ||||||
M | 2024-02-26 | CYAN | Cyanotech Corp | Jensen Glenn | VP, Operations | P - Purchase | $0.31 | +16,835 | 40,000 | +73% | +$5,222 | |||||
D | 2023-12-21 | CYCC | Cyclacel Pharmaceuticals, Inc. | McBarron Paul | See Remarks | P - Purchase | $3.32 | +1,886 | 33,378 | +6% | +$6,252 | |||||
D | 2023-12-21 | CYCC | Cyclacel Pharmaceuticals, Inc. | Rombotis Spiro George | Pres, CEO | P - Purchase | $3.32 | +6,070 | 68,658 | +10% | +$20,122 | |||||
2024-03-04 | DAR | Darling Ingredients Inc. | Jansen Matthew J | COO North America | P - Purchase | $42.76 | +6,000 | 74,065 | +9% | +$256,560 | ||||||
M | 2024-03-13 | DBD | Diebold Nixdorf, Inc | Marquez Octavio | Pres, CEO | P - Purchase | $34.11 | +1,500 | 134,161 | +1% | +$51,167 | |||||
2024-03-08 | DBVT | Dbv Technologies S.A. | Tasse Daniel | CEO | P - Purchase | $0.83 | +17,094 | 17,094 | New | +$14,188 | ||||||
2024-03-13 | DLX | Deluxe Corp | McCarthy Barry C | Pres, CEO | P - Purchase | $19.25 | +2,666 | 173,410 | +2% | +$51,321 | ||||||
D | 2024-02-14 | EBF | Ennis, Inc. | Burnett Vera | CFO, Treasurer | P - Purchase | $20.47 | +716 | 7,335 | +11% | +$14,657 | |||||
2024-03-01 | ELMD | Electromed, Inc. | Cunniff James L. | CEO, Pres | P - Purchase | $15.25 | +9,000 | 10,000 | +900% | +$137,250 | ||||||
AM | 2023-08-25 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | COO | P - Purchase | $0.13 | +121,000 | 680,518 | +22% | +$15,285 | |||||
M | 2024-02-26 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | Co-Pres, COO | P - Purchase | $0.13 | +115,200 | 795,718 | +17% | +$14,694 | |||||
2024-02-27 | ENPH | Enphase Energy, Inc. | Kothandaraman Badrinarayanan | Pres, CEO | P - Purchase | $120.54 | +4,000 | 1,655,171 | 0% | +$482,154 | ||||||
D | 2023-12-22 | ENTX | Entera Bio Ltd. | Toledano Miranda Jayne | CEO | P - Purchase | $0.71 | +23,952 | 110,752 | +28% | +$17,006 | |||||
2024-02-27 | ERII | Energy Recovery, Inc. | Moon David W | Pres, CEO | P - Purchase | $15.51 | +10,750 | 118,160 | +10% | +$166,733 | ||||||
2024-02-22 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.08 | +110,000 | 119,687,407 | 0% | +$8,250 | ||||||
2024-01-05 | FBIO | Fortress Biotech, Inc. | Rosenwald Lindsay A Md | Pres, CEO, COB, 10% | P - Purchase | $2.38 | +50,000 | 2,863,905 | +2% | +$118,770 | ||||||
2023-12-18 | FBRX | Forte Biosciences, Inc. | Wagner Paul A. | See Remarks | P - Purchase | $0.75 | +10,000 | 1,823,236 | +1% | +$7,525 | ||||||
2024-03-07 | FGEN | Fibrogen Inc | Wettig Thane | CEO | P - Purchase | $1.91 | +50,000 | 471,178 | +12% | +$95,470 | ||||||
2024-03-04 | FLNC | Fluence Energy, Inc. | Nebreda Julian | Pres, CEO | P - Purchase | $14.77 | +6,700 | 55,090 | +14% | +$98,926 | ||||||
2024-03-04 | FLNC | Fluence Energy, Inc. | Pasha Ahmed | SVP, CFO | P - Purchase | $15.20 | +3,300 | 3,300 | New | +$50,160 | ||||||
2023-12-20 | FLO | Flowers Foods Inc | Kinsey R Steve | CFO, CAO | P - Purchase | $22.46 | +1,780 | 406,030 | 0% | +$39,982 | ||||||
2024-03-04 | FMC | Fmc Corp | Sandifer Andrew D | EVP, CFO | P - Purchase | $59.22 | +2,150 | 54,432 | +4% | +$127,323 | ||||||
2024-03-15 | FNA | Paragon 28, Inc. | Dacosta Albert | see remarks, 10% | P - Purchase | $9.12 | +28,000 | 11,007,446 | 0% | +$255,226 | ||||||
2024-03-04 | FULC | Fulcrum Therapeutics, Inc. | Sapir Alex | See Remarks | P - Purchase | $11.35 | +43,360 | 43,360 | New | +$492,028 | ||||||
2023-12-26 | GEF | Greif, Inc | Hilsheimer Lawrence A. | EVP, CFO | P - Purchase | $67.59 | +700 | 207,172 | 0% | +$47,312 | ||||||
2023-12-27 | GEF | Greif, Inc | Hilsheimer Lawrence A. | EVP, CFO | P - Purchase | $67.65 | +1,510 | 208,682 | +1% | +$102,149 | ||||||
M | 2024-03-05 | GEF | Greif, Inc | Hilsheimer Lawrence A. | EVP, CFO | P - Purchase | $66.56 | +24,725 | 240,719 | +11% | +$1,645,616 | |||||
M | 2024-03-08 | GEF | Greif, Inc | Rosgaard Ole G | Pres, CEO | P - Purchase | $67.00 | +4,914 | 86,293 | +6% | +$329,235 | |||||
2024-03-08 | GEF | Greif, Inc | Hilsheimer Lawrence A. | EVP, CFO | P - Purchase | $66.50 | +3,843 | 219,931 | +2% | +$255,577 | ||||||
2024-03-07 | GEF | Greif, Inc | Hilsheimer Lawrence A. | EVP, CFO | P - Purchase | $65.06 | +7,363 | 216,088 | +4% | +$479,067 | ||||||
2024-03-06 | GEF | Greif, Inc | Hilsheimer Lawrence A. | EVP, CFO | P - Purchase | $64.40 | +11,500 | 208,725 | +6% | +$740,571 | ||||||
2024-03-05 | GEF | Greif, Inc | Krabill Anthony John | Corporate Treasurer | P - Purchase | $63.12 | +745 | 2,167 | +52% | +$47,027 | ||||||
2024-03-05 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.49 | +30,500 | 5,343,777 | +1% | +$380,945 | ||||||
2024-02-15 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.07 | +12,700 | 5,325,377 | 0% | +$140,589 | ||||||
2024-02-16 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.16 | +10,800 | 5,336,177 | 0% | +$120,528 | ||||||
A | 2024-03-05 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.49 | +3,500 | 5,343,777 | 0% | +$43,715 | |||||
2024-03-04 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.03 | +4,100 | 5,340,277 | 0% | +$53,423 | ||||||
2024-02-07 | GOVX | Geovax Labs, Inc. | Reynolds Mark | CFO | P - Purchase | $2.77 | +2,000 | 7,213 | +38% | +$5,540 | ||||||
M | 2024-02-21 | GOVX | Geovax Labs, Inc. | Dodd David A | Pres, CEO | P - Purchase | $2.27 | +8,729 | 18,661 | +88% | +$19,781 | |||||
2024-02-16 | GTES | Gates Industrial Corp Plc | Jurek Ivo | CEO | P - Purchase | $12.20 | +20,492 | 626,088 | +3% | +$250,002 | ||||||
2024-02-13 | HAIN | Hain Celestial Group Inc | Davidson Wendy P | Pres, CEO | P - Purchase | $9.46 | +5,000 | 58,309 | +9% | +$47,295 | ||||||
2023-12-27 | HRGN | Harvard Apparatus Regenerative Technology, Inc. | He Junli | CEO | P - Purchase | $4.76 | +2,700 | 253,000 | +1% | +$12,852 | ||||||
AM | 2023-11-30 | HSDT | Helius Medical Technologies, Inc. | Andreeff Dane | Pres, CEO, 10% | P - Purchase | $6.41 | +1,284 | 25,586 | +5% | +$8,229 | |||||
2024-02-22 | ILMN | Illumina, Inc. | Thaysen Jacob | CEO | P - Purchase | $135.29 | +7,330 | 14,861 | +97% | +$991,672 | ||||||
2024-02-20 | INM | Inmed Pharmaceuticals Inc. | Adams Eric A | Pres, CEO | P - Purchase | $0.36 | +41,600 | 43,959 | >999% | +$14,922 | ||||||
2023-10-12 | INSP | Inspire Medical Systems, Inc. | Sparks Charisse Y | Chief Medical Officer | P - Purchase | $153.50 | +100 | 998 | +11% | +$15,350 | ||||||
D | 2024-02-01 | INTC | Intel Corp | Gelsinger Patrick P | CEO | P - Purchase | $42.74 | +2,800 | 554,576 | +1% | +$119,671 | |||||
2024-01-29 | INTC | Intel Corp | Gelsinger Patrick P | CEO | P - Purchase | $43.36 | +3,000 | 547,413 | +1% | +$130,083 | ||||||
2024-03-04 | IRWD | Ironwood Pharmaceuticals Inc | Emany Sravan Kumar | SVP, CFO | P - Purchase | $9.38 | +10,684 | 301,733 | +4% | +$100,216 | ||||||
2024-03-01 | JAZZ | Jazz Pharmaceuticals Plc | Johnson Philip L | EVP, CFO | P - Purchase | $119.65 | +12,000 | 27,932 | +75% | +$1,435,800 | ||||||
2023-12-26 | JBSS | Sanfilippo John B & Son Inc | Sanfilippo Jasper Brian Jr | COO, Pres, 10% | P - Purchase | $105.14 | +3,027 | 19,848 | +18% | +$318,259 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |